Loading…
Loading…
DVHGF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DVHGF and 80,000+ other tickers.
See exactly how DVHGF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DVHGF and 80,000+ other tickers.
Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products…
QUEBEC, Aug. 18, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF) is pleased to announce that in connection with an underwritten public offering, it anticipates to list its common shares and warrants offered on the NYSE American LLC with trading expected to commence as early as August 21, 2026 under the symbols "DHGR" and "DHGR WS", respectively, subject to market conditions and final authorization by the NYSE American LLC of the Company's listing application and continued compliance with the exchange rules. The Company will remain listed on the TSX Venture Exchange (the "TSXV").
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering PR Newswire
QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the NYSE American LLC (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of the Company's listing application and continued compliance with the exchange rules.
The primary objective of the study is to evaluate the efficacy of Thykamine™ compared with placebo in the treatment of mild-to-moderate pediatric atopic dermatitis after 12 weeks of twice-daily treatment. Secondary objectives include assessment of the overall safety and tolerability.
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 PR Newswire